Please assess the completion status of the following clinical trial:

Trial Title: Bupivacaine Plus Diclofenac Versus Bupivacaine Alone for Postoperative Pain Relief in Gynecologic Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* gynecologic cancer patients ,i.e. cervical cancer, endometrial cancer, or ovarian tumor suspicious for malignancy~* who has scheduled for operation via laparotomy route~* Women who has ASA physical status I-II~* All of the have age more than 20 years old~* able to communicate in Thai~* Women who agrees to participate in this study~Exclusion Criteria:~* patient who had emergency conditions - indication for emergency operation~* intraoperative cardiac arrhythmia~* operation purpose for only tumor biopsy~  * Women who have abnormal kidney function test (Cr \> 1.5)~ * Women with history of gastrointestinal bleeding~ * Women who take the antiplatelet or anticoagulant medications~ * Women with history of allergy to bupivacaine and NSAIDs~ * Women who cannot evaluated pain score

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- diclofenac and bupivacaine group (Type: EXPERIMENTAL): Twenty mL of bupivacaine was infiltrated into surgical-site peritoneum , divided in 10 sites before closure, and diclofenac 75 mg (3 mL) was intramuscularly injected immediately after complete the procedure and the operative field was covered with sterile adhesive wound dressing.
- bupivacaine only group (Type: PLACEBO_COMPARATOR): Twenty mL of bupivacaine was infiltrated into surgical-site peritoneum, divided in 10 sites before closure and a 3 mL of sterile water was intramuscularly injected immediately after complete the procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).